Multiple cranial nerve palsy

Summary

Multiple cranial nerve palsy (MONDO:0001819) is a disease. A subtype of cranial nerve palsy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	multiple cranial nerve palsy
Mondo ID	MONDO:0001819
DOID	DOID:13866
SNOMED CT	78152008
UMLS	C0154733
MedGen	509636
Is cancer (heuristic)	no

Also known as: multiple cranial nerve palsies

Disease family

This is a subtype of cranial nerve palsy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy › cranial nerve palsy › multiple cranial nerve palsy

Related subtypes (6): fourth cranial nerve palsy, oculomotor nerve paralysis, glossopharyngeal nerve paralysis, Bell’s palsy, abducens nerve palsy, progressive bulbar palsy

Subtypes (1): foix chavany Marie syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.